Smilow Cancer Hospital at Yale New Haven
New Haven, CT
Accepting patients
RENEW
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Activin Receptor IIA Inhibitor
- Placebo
- Closed Label (Masked)
- Phase 3
Accepting patients
ICP-248 With Azacitidine
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.
- BCL-2 Inhibitor
- Phase 1
Accepting patients
AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
- Monoclonal Antibody
- CD47
- Closed Label (Masked)
- Randomization
- Placebo
- Phase 2
Accepting patients
AZTOUND
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
- DNMT1 Inhibitor
- Phase 2/3
- Has results
Accepting patients
MIDAS
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (MIDAS)
- JAK1 Inhibitor
- ACVR1 Inhibitor
- JAK2 Inhibitor
- Randomization
- Phase 2
Accepting patients
DarbeLus
A Phase II Study of Luspatercept Plus Darbepoetin Alfa in Non-mutated SF3B1 Lower-risk Myelodysplastic Syndromes
- Red Blood Cell Stimulant
- Phase 2
Accepting patients
PedAL Screening
Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
- Phase 1/2
Accepting patients
MyeloMATCH Master Protocol
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
- Genetic Sequencing
- Phase 2
Accepting patients
Cirtuvivint
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
- Tyrosine Kinase (TK) Inhibitor
- Dual Specificity TK Inhibitor (DYRK)
- CLK Inhibitor
- Phase 1
Accepting patients
TCR Engineered Donor T-Cells
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
- T Cell (Allogeneic)
- Phase 1
- Has results